InvestorsHub Logo

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating
profile icon
QuantumTravesty Free
07/25/22 11:39 AM
profile icon
RobotDroid Free
06/24/22 10:42 AM
profile icon
blackcat PremiumMember
06/24/22 10:34 AM
profile icon
QuantumTravesty Free
06/24/22 10:21 AM
profile icon
blackcat PremiumMember
06/23/22 4:15 PM
profile icon
blackcat PremiumMember
06/23/22 3:00 PM
profile icon
blackcat PremiumMember
06/23/22 1:00 PM
profile icon
QuantumTravesty Free
06/23/22 12:41 PM
profile icon
blackcat PremiumMember
06/23/22 12:18 PM
profile icon
QuantumTravesty Free
06/23/22 11:52 AM
profile icon
blackcat PremiumMember
06/23/22 10:30 AM
profile icon
QuantumTravesty Free
06/23/22 10:20 AM
profile icon
jchords Free
06/23/22 10:08 AM
profile icon
heyitsmeagain Free
06/22/22 9:35 AM
profile icon
blackcat PremiumMember
06/21/22 5:52 PM
profile icon
TrendTrade2016 PremiumMember
06/20/22 5:00 AM
profile icon
blackcat PremiumMember
06/17/22 1:34 PM
profile icon
QuantumTravesty Free
06/17/22 12:53 PM
profile icon
blackcat PremiumMember
06/17/22 12:15 PM
profile icon
QuantumTravesty Free
06/17/22 12:05 PM
profile icon
blackcat PremiumMember
06/17/22 10:35 AM
profile icon
blackcat PremiumMember
06/16/22 10:20 AM
profile icon
QuantumTravesty Free
06/16/22 10:06 AM
profile icon
blackcat PremiumMember
06/16/22 8:52 AM
profile icon
blackcat PremiumMember
06/15/22 5:32 PM
profile icon
blackcat PremiumMember
06/15/22 4:03 PM
profile icon
blackcat PremiumMember
06/15/22 2:40 PM
profile icon
bandit007 Free
06/15/22 2:40 PM
profile icon
TrendTrade2016 PremiumMember
06/15/22 1:06 PM
profile icon
blackcat PremiumMember
06/15/22 12:04 PM
profile icon
QuantumTravesty Free
06/15/22 11:55 AM
profile icon
blackcat PremiumMember
06/15/22 11:45 AM
profile icon
QuantumTravesty Free
06/15/22 11:42 AM
profile icon
blackcat PremiumMember
06/15/22 11:28 AM
profile icon
TrendTrade2016 PremiumMember
06/15/22 11:12 AM
profile icon
blackcat PremiumMember
06/15/22 11:10 AM
profile icon
TrendTrade2016 PremiumMember
06/15/22 10:41 AM
profile icon
QuantumTravesty Free
06/15/22 10:38 AM

Kintara Therapeutics Inc (KTRA) RSS Feed

Followers
60
Posters
188
Posts (Today)
0
Posts (Total)
1386
Created
01/25/13
Type
Free
Moderators

  https://www.kintara.com/
Kintara Therapeutics is focused on developing unique anti-cancer compounds, supported by a strong scientific rationale for development in indications with established biomarkers, and where patients are failing, or are unable to tolerate, current therapies.

           VAL-083 Shows Potential Against Multiple Cancers 

VAL-083 is a "first-in-class" small molecule chemotherapeutic. Its unique structure provides many valuable benefits, including the targeting of DNA for its therapeutic effect and its ability to cross the blood brain barrier, critical for activity against central nervous system (CNS) tumors.

VAL-083 has completed Pre-Clinical, Phase I and II trials for the treatment of bevacizumab-refractory glioblastoma multiforme (GBM) and is currently being studied in two Phase II biomarker-driven clinical trials for unmethylated-MGMT GBM.

We are also pursuing the development of VAL-083 in the treatment of ovarian cancer.

 

REM-001 is a Proprietary Late Stage Photodynamic Therapy (“PDT”) Platform 

REM-001 has broad utility for the treatment of serious cutaneous oncology indications. REM-001 has been previously studied in four Phase 2 and/or Phase 3 clinical trials in patients with cutaneous metastatic breast cancer (“CMBC”), who had previously received chemotherapy and/or failed radiation therapy.

Zacks Small-Cap Research
https://s27.q4cdn.com/906368049/files/News/2021/Zacks_SCR_Research_10112021_KTRA_Vandermosten.pdf
Based on our DCF model and a 15% discount rate, Kintara Therapeutics is valued at approximately $5.25 per share. Our model applies a 60% probability for VAL-083 in unmethylated GBM, a 50% probability in methylated GBM and a 50% probability of approval and commercialization in REM-001 for CMBC. The model includes contributions from the United States and Europe. Other regions will be included upon further clarity.
Shares Outstanding (mil) 43.2
Current Price (10/8/2021) $0.77
Valuation $5.25.   

11/03/21

Thanks to its promising pipeline and $0.88 share price, 5-star analyst Michael King, of
H.C. Wainwright, sees an attractive entry point for investors.

“We are bullish about KTRA shares for the following five reasons
: (1) The GBM AGILE trial tests VAL-083 in
all three subtypes of GBM, allowing for multiple opportunities for VAL-083 to prove its
efficacy against phenotypically distinct types of the disease.
(2) VAL-083 is a bifunctional
alkylating agent that crosses the blood brain barrier and exhibits very favorable pharmacologic
properties relative TMZ; fulfilling the need for systemic availability in the brain.
(3) VAL-083
has an established favorable safety record, both from initial trials and prior clinical use in
multiple indications.
(4) Dire unmet need in GBM may present relatively low bar for approval.
(5) Phase 3 ready REM-001 is an additional bonus which is not factored into our valuation
assumptions and could potentially deliver value to shareholders while providing a backstop
against downside,” King explained.

Volume:
Day Range:
Last Trade Time:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
New Post